Founders David Epstein and Elizabeth Buck [file photo]
January 30, 2020 06:40 AM ESTUpdated 07:22 AM
Financing

Can­cer-fo­cused Black Di­a­mond vaults on to Nas­daq in $200M+ pub­lic de­but, mark­ing biggest biotech IPO in 2020 so far

Natalie Grover

Reporter

Ver­sant-backed Black Di­a­mond Ther­a­peu­tics has set its sights on an up­sized biotech IPO to kick 2020 off.

The first start­up out of Ver­sant’s

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Trump pledges his sup­port for a change to the IRA long sought by drug­mak­ers

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times